Kesesakan Dan Agresivitas Pada Remaja Di Kawasan Tambak Lorok Semarang

Penelitian ini bertujuan untuk mengetahui hubungan antara kesesakan dengan agresivitas pada remaja yang tinggal di Kawasan Tambak Lorok Semarang. Populasi dalam penelitian ini adalah remaja yang tinggal di Kawasan Tambak Lorok Semarang. Pengumpulan data menggunakan dua buah skala yaitu, Skala Agresivitas (22 aitem; α=0,864) dan Skala Kesesakan (16 aitem; α=0,828). Subjek penelitian berjumlah 230 remaja yang tinggal di Kawasan Tambak Lorok Semarang yang dipilih melalui teknik simple random sampling. Hasil analisis data menggunakan teknik analisis regresi sederhana menunjukkan terdapat hubungan positif antara kesesakan dengan agresivitas pada remaja yang tinggal Kawasan Tambak Lorok Semarang (r=0,578; p=0,000). Semakin tinggi kesesakan yang dirasakan subjek maka semakin tinggi agresivitas. Kesesakan memberikan sumbangan efektif sebesar 33,4% pada agresivitas dan sisanya sebesar 66,6% dipengaruhi oleh faktor lain yang tidak diteliti dalam penelitian ini

Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor Supplementary Figure 3

Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor Supplementary Figure 3</p

Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor Supplementary Figure 4

Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor Supplementary Figure 4</p

Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor Supplementary Figure 2

Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor Supplementary Figure 2</p

Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor Supplementary Figure 1

Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor Supplementary figure</p

Additional file 2 of EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers

Additional file 2: Table S2. Detailed information of gene mutations in NSCLCs from OAK and POPLAR clinical trials

Additional file 1 of EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers

Additional file 1: Table S1. Detailed information of EPHA5 mutations in NSCLCs from MSKCC cohort

Additional file 3 of EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers

Additional file 3: Fig. S1. Survival analysis divided in four groups: EPHA5 mutation with metastases > 3, EPHA5 mutation with metastases ≤ 3, EPHA5 no mutation with metastases > 3, and EPHA5 no mutation with metastases ≤ 3 (P = 0.0004)

DataSheet_6_Whole-Exome Sequencing Uncovers Specific Genetic Variation Difference Based on Different Modes of Drug Resistance in Small Cell Lung Cancer.pdf

The poor survival rate of small cell lung cancer (SCLC) is mainly related to the condition that patients with SCLC often have good responses to first-line chemotherapy initially, but later on, most of these patients relapse rapidly due to resistance to further treatment. In this study, we attempted to analyze whole-exome sequencing data based on the largest sample size to date, to develop a classifier to predict whether a patient will be chemorefractory or chemosensitive and to explicate the risk of recurrence that affects the prognosis of patients. We showed the different characteristics of somatic mutational signatures, somatic mutation genes, and distinct genome instability between chemorefractory and chemosensitive SCLC patients. Amplified mutations in the chemosensitive group inhibited the regulation of the cell cycle process, transcription factor binding, and B-cell differentiation. Analysis of deletion mutation also suggested that detection of the chromosomal-level variation might influence our treatment decisions. Higher PD-L1 expressions (based on TPS methods) were mostly present among chemosensitive patients (p = 0.026), while there were no differences in PD-L1 expressions (based on CPS methods) and CD8+ TILs between the two groups. According to the model determined by logistic regression, each sample was endowed with a predictive probability value (PV). The samples were divided into a high-risk group (>0.55) and a low-risk group (≤0.55), and the survival analysis showed obvious differences between the two groups. This study provides a reference basis to translate this knowledge into practice, such as formulating personalized treatment plans, which may benefit Chinese patients with SCLC.</p

DataSheet_2_Whole-Exome Sequencing Uncovers Specific Genetic Variation Difference Based on Different Modes of Drug Resistance in Small Cell Lung Cancer.pdf

The poor survival rate of small cell lung cancer (SCLC) is mainly related to the condition that patients with SCLC often have good responses to first-line chemotherapy initially, but later on, most of these patients relapse rapidly due to resistance to further treatment. In this study, we attempted to analyze whole-exome sequencing data based on the largest sample size to date, to develop a classifier to predict whether a patient will be chemorefractory or chemosensitive and to explicate the risk of recurrence that affects the prognosis of patients. We showed the different characteristics of somatic mutational signatures, somatic mutation genes, and distinct genome instability between chemorefractory and chemosensitive SCLC patients. Amplified mutations in the chemosensitive group inhibited the regulation of the cell cycle process, transcription factor binding, and B-cell differentiation. Analysis of deletion mutation also suggested that detection of the chromosomal-level variation might influence our treatment decisions. Higher PD-L1 expressions (based on TPS methods) were mostly present among chemosensitive patients (p = 0.026), while there were no differences in PD-L1 expressions (based on CPS methods) and CD8+ TILs between the two groups. According to the model determined by logistic regression, each sample was endowed with a predictive probability value (PV). The samples were divided into a high-risk group (>0.55) and a low-risk group (≤0.55), and the survival analysis showed obvious differences between the two groups. This study provides a reference basis to translate this knowledge into practice, such as formulating personalized treatment plans, which may benefit Chinese patients with SCLC.</p